Sunshine Biopharma, Inc.
SBFM
Rank in Stocks
#30148
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Share Price
$2.75
Last synced: 2026-11-09
Market Cap
$5.84M
Change (1 day)
1.48%
Change (1 year)
-84.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sunshine Biopharma, Inc. (SBFM)
Category
Healthcare
Operating Margin for Sunshine Biopharma, Inc. (SBFM)
Operating Margin as of November 2026 TTM: -14.71%
According to Sunshine Biopharma, Inc.'s latest financial reports, its current operating margin (TTM) is -14.71%. At the end of 2025 the company had an operating margin of -12.34%.
Operating Margin history for Sunshine Biopharma, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -14.71% | 19.21% |
| 2025 | -12.34% | -25.97% |
| 2024 | -16.67% | -16.06% |
| 2023 | -19.86% | -96.80% |
| 2022 | -621.28% | -41.84% |
| 2021 | -1,068.18% | 32.23% |
| 2020 | -807.83% | -73.41% |
| 2019 | -3,037.91% | 1,064.13% |
| 2018 | -260.96% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -45,667.45% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -101.32% |
DE
|
|
| 19.68% | -101.34% |
DE
|
|
| 13.26% | -100.90% |
JP
|
|
| 17.08% | -101.16% |
CH
|
|
| 14.92% | -101.01% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sunshine Biopharma, Inc.'s operating margin
What is Sunshine Biopharma, Inc.'s operating margin?
Sunshine Biopharma, Inc.'s operating margin is -14.71%, as of Nov 2026.
What was Sunshine Biopharma, Inc.'s operating margin in 2025?
In 2025, Sunshine Biopharma, Inc.'s operating margin was -12.34%, compared with -16.67% in 2024.
How has Sunshine Biopharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Sunshine Biopharma, Inc.'s operating margin was highest in 2025 (-12.34%) and lowest in 2021 (-1,068.18%).
How does Sunshine Biopharma, Inc.'s operating margin compare with similar companies?
Sunshine Biopharma, Inc.'s operating margin (-14.71%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.